fda compounding semaglutide crackdown news today 2025 Troubling Findings in Study of GLP-1 Compounders September 2, 2025: U.S. compounding

Unregulated Injectable Products A major concern outside controlled laboratory settings is that injectable peptides like GHK-Cu are not approved as medicines by regulatory authorities such as the FDA or the EMA

Blood sugar control Both medications improve insulin sensitivity and stabilize glucose levels, which directly affects fat storage

Energy Boost: The injections may provide an energy boost, supporting individuals in adopting more active lifestyles

Participants completed original and adapted forms of validated assessments (see Supplemental document)

[12] The most widely recommended treatment for NAFLD is weight loss (of 7% to 10% body weight)

Hsu, W.H